



Nominations for Appointment to the Grants Working Group (GWG)

Appointment of New Members

Barbara White, MD

Barbara White, MD, is currently Chief Medical Officer of Corbus Pharmaceuticals Inc. In this role, she provides overall leadership to clinical development at Corbus, with responsibility for all product development activities. Dr. White's industry experience includes phase 1-4 clinical development experience in inflammatory and autoimmune diseases. She also has industry experience in pre-clinical drug development, translational medicine, personalized medicine, and medical affairs.

Prior to her work at Corbus, Dr. White was senior vice president and head of R&D for Stiefel, a GSK company that focused on medications and consumer products in dermatology. She has held prior roles as head of clinical development in Inflammation in UCB and in Inflammation, Autoimmunity, and Respiratory at MedImmune/AstraZeneca. Dr. White began her career in industry in Medical Affairs at Amgen. Prior to her pharmaceutical career, Dr. White was Professor of Medicine and Vice Chair for Research in the Department of Medicine at the University of Maryland School of Medicine. Her academic research focused on T cells and immune-mediated mechanisms of lung fibrosis in scleroderma. Dr. White also previously served as co-director of the Johns Hopkins University and University of Maryland Scleroderma Center. She served on the Board of Directors and was Chair of the Committee on Research of the American College of Rheumatology.

Dr. White received her medical degree from the University of Pennsylvania School of Medicine and is board certified in internal medicine, rheumatology and allergy/clinical immunology. She completed her postdoctoral studies in basic cellular immunology at the National Institutes of Health.

Reappointment of Scientific Members to the Grants Working Group

Grants Working Group Members originally appointed in 2008 have terms that are now expiring or just expired. We are seeking the reappointment of the individuals listed in the table below. Their updated biographies follow. In accordance with the rules set forth by Proposition 71, reappointments should be staggered into thirds, each with a 2, 4, or 6-year term. For these two individuals, we propose 6-year reappointment terms.

Proposed Reappointments to GWG

Last	First	Term (Yrs.)	Expertise
Lake	John R.	6	Liver; Solid Organ Transplantation; Cellular Therapeutics for Liver Disease
Rubin	Josh	6	Pediatric Brain Tumors; Brain Development Mechanisms & Tumorigenesis

John R. Lake, MD

John R. Lake, MD, is a Professor of Surgery and Medicine and is the Director of the Liver Transplant Program at the University of Minnesota Medical School. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center.

Dr. Lake received his medical degree from the University of Minnesota Medical School and completed his residency and fellowship training at the University of California, San Francisco. Prior to moving to the University of Minnesota in 1998, he helped start, and was the Medical Director of, the Liver Transplant Program at the University of California, San Francisco.

Dr. Lake's research interests include post-transplant hepatitis C, predictors of outcomes following liver transplantation, and the development of new immunosuppressive agents. He has authored more than 170 articles and 20 reviews in peer-reviewed journals and more than 25 book chapters. He is currently the Editor for the journal Liver Transplantation and is on the Editorial Boards for several other scientific journals.

In addition, Dr. Lake is a past-president of the American Society of Transplantation. He is a past-president of the United Network for Organ Sharing, where he continues to serve on the Corporate Advisory Committee. He is also the past-chair of the American Board of Internal Medicine Test and Policy Committee on Transplant Hepatology.

Josh Rubin, MD, PhD

Josh Rubin, MD, PhD, is an Associate Professor of Pediatrics in the Department of Hematology and Oncology and the Department of Anatomy and Neurobiology

at the Washington University School of Medicine in St. Louis. He also serves as the Co-Director of Pediatric Neuro-Oncology at St Louis Children's Hospital and Co-Leader of the Neuro-Oncology Focus Group at The Siteman Cancer Center. Dr. Rubin received his medical degree and his doctoral degree from Albert Einstein College of Medicine; completed a residency at the Harvard-affiliated Children's Hospital; and then completed a fellowship in Hematology/Oncology and postdoctoral work at Children's Hospital and the Dana Farber Cancer Institute.

Dr. Rubin's laboratory studies the biology and treatment of pediatric brain tumors. There are three primary focus areas of research including: 1) The molecular basis for sex differences in brain tumors, 2) mechanisms of CXCR4 and cAMP regulation of brain tumor stem cell function and 3) the biology of brain tumor perivascular stem cell niche. Within each of these focus areas are basic science and translational science projects.

In addition to his clinical and leadership responsibilities at Washington University, Dr. Rubin also serves as the Chair of the Scientific Advisory Board of the Children's Brain Tumor Foundation, a national advocacy and research support organization, and as the Scientific Advisor to The Taylor Rozier's Hope for a Cure Foundation, a St Louis-based brain tumor research support organization.